Kimberly Burlison | Market Access, North America
Orchard Therapeutics

Kimberly Burlison leads the North America Market Access function at Orchard Therapeutics, where she is responsible for U.S. access strategy for Lenmeldy, a first-in-class gene therapy for metachromatic leukodystrophy, a rare and life-threatening pediatric disease. She brings deep expertise in payer strategy, reimbursement, and innovative access models for high-cost therapies, informed by prior leadership roles at EQRx and the Blue Cross Blue Shield Association. Kimberly is recognized for her patient-centered approach and her work advancing sustainable access frameworks in the rapidly evolving cell and gene therapy landscape.